迪瑞医疗
(300396)
| 流通市值：37.35亿 | | | 总市值：37.39亿 |
| 流通股本：2.72亿 | | | 总股本：2.73亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 393,260,256.23 | 586,680,294.87 | 471,019,852.83 | 445,379,575.9 |
| 结算备付金 | 0 | 0 | - | - |
| 拆出资金 | 0 | 0 | - | - |
| 衍生金融资产 | 0 | 0 | - | - |
| 应收票据及应收账款 | 441,722,093.25 | 442,251,234.18 | 591,080,039.4 | 589,621,530.98 |
| 其中：应收票据 | 0 | 561,183 | 0 | 321,908.59 |
| 应收账款 | 441,722,093.25 | 441,690,051.18 | 591,080,039.4 | 589,299,622.39 |
| 应收款项融资 | 0 | 0 | - | - |
| 预付款项 | 18,253,548.49 | 17,195,132.56 | 19,289,059.62 | 29,668,268.07 |
| 应收保费 | 0 | 0 | - | - |
| 应收分保账款 | 0 | 0 | - | - |
| 应收分保合同准备金 | 0 | 0 | - | - |
| 其他应收款合计 | 6,928,365.42 | 8,564,219.16 | 4,448,918.98 | 4,700,015.59 |
| 其中:应收利息 | 0 | 0 | - | - |
| 应收股利 | 0 | 0 | - | - |
| 买入返售金融资产 | 0 | 0 | - | - |
| 存货 | 559,041,927.84 | 576,420,879.57 | 492,717,834.54 | 523,761,953.54 |
| 合同资产 | 0 | 0 | - | - |
| 一年内到期的非流动资产 | 153,315,368.7 | 151,319,748.58 | 151,938,103.29 | 133,618,272.08 |
| 其他流动资产 | 62,605,662.67 | 61,679,332.9 | 28,333,564.64 | 27,112,475.54 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 1,635,127,222.6 | 1,844,110,841.82 | 1,778,827,373.3 | 1,753,862,091.7 |
| 非流动资产: | | | | |
| 发放委托贷款及垫款 | 0 | 0 | - | - |
| 债权投资 | 0 | 0 | - | - |
| 其他债权投资 | 0 | 0 | - | - |
| 长期应收款 | 175,239,820.92 | 184,536,219.06 | 223,157,642.31 | 237,953,245.08 |
| 长期股权投资 | 454,373,373.16 | 450,858,277.53 | 450,005,002.15 | 444,550,722.87 |
| 其他权益工具投资 | 117,382,800 | 117,382,800 | 109,547,381.67 | 109,547,381.67 |
| 其他非流动金融资产 | 0 | 0 | - | - |
| 投资性房地产 | 46,763,470.62 | 47,268,484.58 | 47,773,498.54 | 48,278,512.51 |
| 固定资产 | 184,652,745.6 | 183,783,169.34 | 182,860,862.88 | 178,731,338.93 |
| 在建工程 | 836,276.11 | 254,293.21 | 24,752.48 | 12,376.24 |
| 生产性生物资产 | 0 | 0 | - | - |
| 油气资产 | 0 | 0 | - | - |
| 使用权资产 | 7,554,690.43 | 6,002,079.18 | 7,881,955.13 | 9,679,361.53 |
| 无形资产 | 65,872,668.13 | 68,742,132.33 | 58,728,074.57 | 61,551,728.34 |
| 开发支出 | 29,241,586.63 | 28,047,984.62 | 32,875,082.09 | 30,696,491.83 |
| 商誉 | 0 | 0 | - | - |
| 长期待摊费用 | 10,995,895.32 | 12,778,200.34 | 11,078,377.46 | 12,115,216.32 |
| 递延所得税资产 | 18,802,123.89 | 16,136,487.8 | 15,815,081.35 | 15,702,734.55 |
| 其他非流动资产 | 148,516,134.6 | 147,632,418.46 | 152,375,145.11 | 141,921,574.53 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 1,260,231,585.41 | 1,263,422,546.45 | 1,292,122,855.74 | 1,290,740,684.4 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 2,895,358,808.01 | 3,107,533,388.27 | 3,070,950,229.04 | 3,044,602,776.1 |
| 流动负债: | | | | |
| 短期借款 | 129,617,361.11 | 175,117,361.11 | 385,099,000 | 315,099,000 |
| 向中央银行借款 | 0 | 0 | - | - |
| 吸收存款及同业存放 | 0 | 0 | - | - |
| 拆入资金 | 0 | 0 | - | - |
| 交易性金融负债 | 0 | 0 | - | - |
| 衍生金融负债 | 0 | 0 | - | - |
| 应付票据及应付账款 | 337,165,532.02 | 416,018,974.15 | 459,210,624.22 | 495,304,915.58 |
| 其中：应付票据 | 195,259,661.89 | 158,161,854.02 | 185,833,361.97 | 194,581,940.88 |
| 应付账款 | 141,905,870.13 | 257,857,120.13 | 273,377,262.25 | 300,722,974.7 |
| 预收款项 | 48,170.2 | 132,595.04 | 46,371.63 | 472,052.69 |
| 合同负债 | 48,458,911.5 | 49,664,391.75 | 38,314,399.5 | 37,287,882.5 |
| 卖出回购金融资产款 | 0 | 0 | - | - |
| 应付手续费及佣金 | 0 | 0 | - | - |
| 应付职工薪酬 | 5,350,941.76 | 6,102,312.87 | 3,433,014.97 | 17,651,744.91 |
| 应交税费 | 2,410,372.43 | 1,874,315.04 | 3,524,544.98 | 11,665,963.12 |
| 其他应付款合计 | 27,689,236.88 | 33,284,210.82 | 26,686,971.63 | 38,773,100.54 |
| 其中:应付利息 | 0 | 0 | - | - |
| 应付股利 | 0 | 0 | - | - |
| 应付分保账款 | 0 | 0 | - | - |
| 保险合同准备金 | 0 | 0 | - | - |
| 代理买卖证券款 | 0 | 0 | - | - |
| 代理承销证券款 | 0 | 0 | - | - |
| 一年内到期的非流动负债 | 8,404,533.37 | 10,136,307.25 | 8,812,062.76 | 8,705,821.26 |
| 其他流动负债 | 3,798,012.69 | 4,978,544.68 | 3,346,059.19 | 3,455,516.94 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 562,943,071.96 | 697,309,012.71 | 928,473,048.88 | 928,415,997.54 |
| 非流动负债: | | | | |
| 长期借款 | 215,013,333.33 | 318,213,333.33 | - | - |
| 应付债券 | 0 | 0 | - | - |
| 优先股 | 0 | 0 | - | - |
| 永续债 | 0 | 0 | - | - |
| 租赁负债 | 3,760,005.68 | 0 | 901,277.57 | 1,323,666.65 |
| 长期应付款 | 0 | 0 | - | - |
| 长期应付职工薪酬 | 0 | 0 | - | - |
| 预计负债 | 0 | 0 | - | - |
| 递延收益 | 17,614,044.68 | 17,860,271.25 | 18,106,497.82 | 18,352,724.39 |
| 递延所得税负债 | 26,251,484.9 | 25,381,443.06 | 27,073,872.37 | 27,170,528.38 |
| 其他非流动负债 | 0 | 0 | - | - |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 262,638,868.59 | 361,455,047.64 | 46,081,647.76 | 46,846,919.42 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 825,581,940.55 | 1,058,764,060.35 | 974,554,696.64 | 975,262,916.96 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 272,700,161 | 272,700,161 | 272,700,161 | 274,565,911 |
| 其他权益工具 | 0 | 0 | - | - |
| 优先股 | 0 | 0 | - | - |
| 永续债 | 0 | 0 | - | - |
| 资本公积 | 243,616,718.29 | 243,616,718.29 | 245,330,178.55 | 258,202,613.55 |
| 减:库存股 | 0 | 0 | 1,713,460.26 | 16,451,645.26 |
| 其他综合收益 | 44,880,049.24 | 39,549,892.45 | 36,514,093.85 | 36,793,176.29 |
| 专项储备 | 0 | 0 | - | - |
| 盈余公积 | 137,986,102.82 | 137,986,102.82 | 137,986,102.82 | 137,986,102.82 |
| 一般风险准备 | 0 | 0 | - | - |
| 未分配利润 | 1,370,582,580.03 | 1,354,903,896.37 | 1,405,558,784.43 | 1,378,224,297.52 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 2,069,765,611.38 | 2,048,756,770.93 | 2,096,375,860.39 | 2,069,320,455.92 |
| 少数股东权益 | 11,256.08 | 12,556.99 | 19,672.01 | 19,403.22 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 2,069,776,867.46 | 2,048,769,327.92 | 2,096,395,532.4 | 2,069,339,859.14 |
| 负债和股东权益合计 | 2,895,358,808.01 | 3,107,533,388.27 | 3,070,950,229.04 | 3,044,602,776.1 |
| 公告日期 | 2025-04-26 | 2025-03-29 | 2024-10-25 | 2024-08-23 |
| 审计意见(境内) | | 标准无保留意见 | | |